Singular Health Group Ltd (shg) Logo

Singular Health Group Ltd (SHG)

___:___ · Healthcare

SHG Chart


SHG's Principal Activity is the sale and development of medical imaging and visualisation software and technology.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -63.53%


Market Capitalisation
ASX Rank 1,933 of 2,316
Sector Rank 179 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies ILA / MEB / SCU
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

SHG is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Singular Health Group Ltd (SHG) is a technology-driven medical imaging company based in Australia with the mission of developing technologies that provide patients and practitioners with access to personalised, enhanced, medical data to inform better health decisions.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Subiaco WA 6008
Registry Automic Group
Auditor Moore Australia Audit (WA)
Date Listed 12 Feb 2021

Upcoming Calendar (Forecasted)

Date Event
25/02/2022 Report (Interim)
30/08/2022 Report (Prelim)
29/09/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Andrew Ian Just Non-Executive Director Jan 2021 Director Bio icon

Mr Andrew Ian Just

Non-Executive Director

Mr Just was employed by Roche Pharmaceuticals as a Health Economist. He built economic models for inclusion of Roche products on the Australian Medical Benefits Scheme and then in GE Healthcare where he was appointed General Manager of Services for Australia and New Zealand. He has since gained over 25 years of senior executive experience in the healthcare industry at Fortune 500 and ASX listed companies including Stryker, Cochlear, GE Healthcare, Radiometer, Roche, and Novartis. Andrew has prior ASX experience having previously been the Chief Executive Officer and Managing Director of ASX listed company Paragon Care Limited (ASX:PGC). He is also Chairman of Risk Committee of SHG.

Mr Howard Andrew Digby Non-Executive Chairman,Non-Executive Director Jan 2021 Director Bio icon

Mr Howard Andrew Digby

Non-Executive Chairman,Non-Executive Director

Mr Digby began his career at IBM and has spent over 25 years managing technology-related businesses in the Asia Pacific region, of which 11 years were spent in Hong Kong. Prior to returning to Perth, Howard was with The Economist Group as Regional Managing Director. He has also held senior regional management roles at Adobe and Gartner. Currently a Non-Executive Director of 4DS Memory (ASX:4DS), Elsight (ASX:ELS), Cirralto (ASX:CRO), Vortiv (ASX:VRO) and previously a Non-Executive Director of ImeHXS (ASX:IME), Howard has ASX and corporate governance experience with technology and digital health companies. He is also member of the Risk Committee of SHG.

Dr Kwang Guan Tay Executive Director Feb 2020 Director Bio icon

Dr Kwang Guan Tay

Executive Director

Dr Tay has held various academic positions over the past 20 years (primarily in an adjunct or visiting capacity) at the University of Western Australia, as well as Edith Cowan University. Guan has knowledge in the medical and educational sectors. He is currently an Adjunct Associate Professor at the Faculty of Health and Medical Sciences at the University of Western Australia. Dr Tay has also managed projects at Khalifa University, the premier research-intensive university in Abu Dhabi, the United Arab Emirates.

Mr Denning Sang-Tatt Chong Founder,Non-Executive Director Feb 2020 Director Bio icon

Mr Denning Sang-Tatt Chong

Founder,Non-Executive Director

Mr Chong has been the principal of James Chong Lawyers since 2004. Denning has had worked across a range of the community - from ASX listed companies and cross border type transactions, to local communities. Denning holds directorships with various property development companies, including currently being a director of the Australian subsidiaries of a SGX listed property developer, with a property portfolio. He is also a director of a boutique venture capital business focusing on property, financial and medical technology sectors. He is also member of the Risk Committee of SHG.

Mr Thomas Sylvanus Hanly Chief Executive Officer,Managing Director Feb 2020 Director Bio icon

Mr Thomas Sylvanus Hanly

Chief Executive Officer,Managing Director

Mr Hanly in his early career has worked as an economic analyst for AgricultureNZ, before moving to the United States where he obtained his Series 7 and was employed in private banking with Merrill Lynch. With an understanding of capital markets and an interest in technology, he was involved in the early 2000's driving the development and commercialization of a financial services start-up in the United States before returning to Australia. Prior to joining Singular Health, Thomas has held a number of board positions of privately held companies in Australia and Singapore and has acted as an independent consultant assisting with the funding and commercialization of innovative technologies. Recently, Thomas provided strategic technology transfer advice for the development of new acid leach membrane technology from Monash University and helped to develop carbon tax offset strategies with Calibre Group in Perth.

Mr Steven Wood Company Secretary N/A

Director Interests

The current holdings of SHG directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Howard Digby 27/01/2021 50,000 35,000 1,000,000 N/A
Andrew Just 27/01/2021 N/A N/A 1,000,000 N/A
Thomas Hanly 20/02/2020 1 3,500,000 6,000,000 N/A
Denning Chong 20/02/2020 N/A 4,380,000 4,500,000 N/A
Kwang Tay 20/02/2020 157,398 N/A 3,000,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Feb 11, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Sim Tek Tan 8,780,000 8.59%
Chong Ling Diamond Cheong 7,065,754 6.91%
CS Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) 6,280,000 6.14%
JLI Enterprises Pty Ltd (JLI A/C) 4,900,000 4.79%
JCC Health Pty Ltd (The Jde Medvr A/C) 4,380,000 4.28%
Pak Lim Kong 4,073,973 3.99%
Sylvan Capital Pte Ltd 3,500,000 3.42%
SC Consultant Pty Ltd 3,161,918 3.09%
Garry Tet Kheng Chong 3,000,000 2.93%
Wang (Aust) Pty Ltd 2,840,000 2.78%
Peninsula Treescape Pty Ltd 2,700,000 2.64%
Fayweng Pty Ltd 2,000,000 1.96%
Design House (Wa) Pty Ltd 2,000,000 1.96%
Stained Glass Windows Pty Ltd 2,000,000 1.96%
Sandhurst Trustees Ltd (Cyan C3G Fund A/C) 2,000,000 1.96%
Mr Philip John Cawood 1,804,795 1.77%
Richard Tai Pty Ltd 1,500,000 1.47%
Jebtai Pty Ltd 1,500,000 1.47%
Ausglobal One Pty Ltd 1,053,974 1.03%
Dong Chang 1,050,959 1.03%
Grange Consulting Group Pty Ltd 1,000,000 0.98%
Pac Asset Management Pty Ltd 996,850 0.98%
National Nominees Limited 925,000 0.90%
Lombardi Super Pty Ltd 850,000 0.83%
Royanna Pty Ltd 850,000 0.83%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1 7 133 314 101 556

Substantial Shareholders

No Substantial Shareholders for SHG in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
SHG Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.